Colorectal cancer is the third most common malignancy worldwide. In these patients, the peritoneum is the second most common place of recurrence.[@CR1]^,^[@CR2] Published incidence rates of metachronous PM are influenced by characteristics of the colorectal cancer population, as well as the method of detection. Sensitivity of imaging is low for the small flat peritoneal lesions, and metachronous PM might remain undetected unless surgical re-exploration is performed.[@CR3] Consequently, incidences may be underestimated. Prognosis is generally poor at time of diagnosis, with a median survival of approximately 5 months when untreated.[@CR4]^,^[@CR5]

Published risk factors for the development of metachronous PM in colorectal cancer are advanced tumor (T) and nodal (N) status, mucinous histology, emergency surgery, and non-radical resection of the primary tumor.[@CR6]^,^[@CR7] Emergency surgery is mostly performed for either tumor perforation, obstruction, or bowel perforation proximal to an obstructing cancer. In a systematic review by Honoré et al., tumor perforation was identified as a risk factor for metachronous PM. Regarding obstruction, the authors stated that no increased risk for the development of metachronous PM was reported in 12 large series, although this association was not part of the aims of these studies.[@CR8] The authors updated their review in 2017, and no new data to modify their conclusion on obstruction as a risk factor for peritoneal recurrence was available.[@CR9]

In 2017, a nationwide collaborative research project on left-sided obstructing colon cancer (LSOCC) was performed in the Netherlands.[@CR10] Given the paucity of data on PM in patients with obstructing colon cancer, the primary aim of this study was to determine the incidence of synchronous PM and cumulative metachronous PM rate using this large dataset. Secondary objectives were to provide independent predictors of metachronous PM in this patient population, and to evaluate therapeutic and prognostic implications.

Methods {#Sec1}
=======

Study Design {#Sec2}
------------

A collaborative, national research project was performed by the Dutch Snapshot Research Group (DSRG) according to a previously published protocol.[@CR10] Short-term data of patients with a registered resection of LSOCC between 2009 and 2016 were retrieved from the Dutch Colorectal Audit (DCRA). In this national, prospective (mandatory) database, all patients with colorectal cancer had undergone either emergency or elective surgical resection for primary colorectal cancer. Left-sided resections were defined as resection for a tumor located in the splenic flexure, descending colon or sigmoid. Additional baseline, procedural, and long-term outcome data were retrospectively gathered from original patient files by surgical residents between August and December 2017.[@CR11] The design of this study and preparation of the manuscript were performed according to the Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) guidelines.[@CR12]

Inclusion/Exclusion Criteria {#Sec3}
----------------------------

After collection of additional diagnostic data from the original patient files, only patients with a documented symptomatic colonic obstruction with complaints of either nausea, vomiting, and/or abdominal distention with confirmation of the obstruction on X-ray or computed tomography (CT) were considered as a diagnosis of LSOCC. Patients without proven malignancy, an extracolonic malignancy, and/or signs of bowel perforation on CT at baseline were excluded.

Outcome Parameters and Definitions {#Sec4}
----------------------------------

The main outcomes of this study were the incidence of synchronous PM and cumulative metachronous PM rate. Secondary outcomes included risk factors for the development of metachronous PM, and treatment of PM.

Synchronous PM were defined as PM present at time of diagnosis or observed within 30 days after resection of the primary tumor according to Segelman et al.[@CR6] Metachronous PM included PM observed after 30 days following primary tumor resection. For analyses of synchronous PM, all patients were included independent of intention of treatment. For analyses of metachronous PM, patients were excluded if they had synchronous PM, palliative treatment intent post-resection, palliative treatment intent based on review of original patient files, or if patients died within 30 days postoperatively. For synchronous PM, overall survival included the interval between first presentation and death by any cause, or last follow-up. For metachronous PM, overall survival was defined as the interval from primary tumor resection until death by any cause or last follow-up. Treatment was categorized as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or other modalities.

Statistical Analysis {#Sec5}
--------------------

Normally distributed continuous outcomes are reported as means with standard deviation (SD) and analysed with Student's *t* test. Non-normally distributed continuous data are shown as medians with interquartile range (IQR) and compared with the Mann--Whitney *U* test. Categorical variables are presented as percentages and compared with the *X*^2^ test or Fisher's exact test. Kaplan--Meier analysis was used to determine the cumulative metachronous PM rate. To determine independent risk factors for the development of metachronous PM, Cox regression analyses were performed. Covariates were included in the univariable Cox regression analysis based on previous literature in combination with initial analyses of baseline and procedural characteristics. Covariates with a *p*-value of \< 0.2 after univariable analysis were included in the multivariable Cox regression model to identify individual risk factors for the development of metachronous PM. Overall survival was calculated and plotted using Kaplan--Meier analysis for the different predefined subgroups and compared using the log-rank test. A two-sided *p* value of \< 0.05 was considered statistically significant. Analyses were performed with IBM SPSS statistics, version 25.0 (IBM Corp Amonk, NY, USA).

Ethics {#Sec6}
------

The Institutional Review Board of the Academic Medical Center in Amsterdam (the Netherlands) approved this study, with exemption status for individual informed consent because of the retrospective, anonymized data analyses.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

Of the 77 hospitals in the Netherlands in 2017, 75 hospitals participated, resulting in a registration of 3879 potentially eligible patients (Fig. [1](#Fig1){ref-type="fig"}). After applying strict inclusion criteria, mainly related to a confirmed diagnosis of acute colonic obstruction without signs of bowel perforation, 3038 patients remained for analysis on synchronous PM. A total of 2407 patients were included for analyses on metachronous PM, after exclusion of patients with synchronous PM (*N* = 148), patients with palliative intention of treatment (*N* = 367), and patients who died within 30 days after resection (*N* = 116).Fig. 1Patient selection

Synchronous Peritoneal Metastases {#Sec9}
---------------------------------

### Baseline and Procedural Characteristics {#Sec10}

Presence of PM at diagnosis of the primary tumor or until 30 days postoperatively was missing in 62 of 3038 patients (2.0%). Of the remaining 2976 patients, synchronous PM were present in 148 patients (5.0%). The peritoneum was the only site of metastatic disease in 67 patients (45.6%). Patients with synchronous PM were significantly younger (median 66 vs. 71 years, *p* \< 0.001), and more often had a pT4 stage (63.0% vs. 27.9%, *p* \< 0.001) and pN2 stage (54.2% vs. 21.6%, *p* \< 0.001) when compared to patients without synchronous PM (Table [1](#Tab1){ref-type="table"}). Resection of the primary tumor was more often incomplete in the synchronous PM group (13.4% vs. 4.3%, *p* \< 0.001).Table 1Baseline and surgical characteristics of patients who underwent resection of left-sided obstructive colon cancer, stratified for detection of synchronous peritoneal metastasesSynchronous peritoneal metastases\
*N* = 148 (%)No synchronous peritoneal metastases\
*N* = 2828 (%)*P*Sex (*N* = 2976)0.493 Male86/148 (58.1)1562/2828 (55.2) Female62/148 (41.9)1266/2828 (44.8)Median age in years (i.q.r) (*N* = 2976)66.0 (60.0--75.0)71.0 (62.0--79.0)\< 0.001Mean BMI in kg/m^2^ (SD) (*N* = 2516)24.8 (3.9)25.4 (4.3)0.103ASA score (*N* = 2947)0.788 ASA I-II99/145 (68.3)1883/2802 (67.2) ASA III-IV46/145 (31.7)919/2802 (32.8)Comorbidity (*N* = 2961)102/145 (70.3)1981/2816 (70.3)0.999Previous abdominal surgery (*N* = 2948)33/146 (22.6)840/2802 (30.0)0.057Tumour localization (*N* = 2976)0.487 Sigmoid106/148 (71.6)1956/2828 (69.2)0.528 Descending colon21/148 (14.2)508/2828 (18.0)0.242 Splenic flexure21/148 (14.2)364/2828 (12.9)0.641Tumour histology (*N* = 2927)0.023 Adenocarcinoma133/143 (93.0)2660/2784 (95.5)0.157 Mucinous tumour6/143 (4.2)105/2784 (3.8)0.796 Signet-ring cell tumour4/143 (2.8)12/2784 (0.4)0.006 Other0/143 (0.0)7/2784 (0.3)1.000Tumour differentiation (*N* = 1924)0.010 Well/moderate78/93 (83.9)1689/1831 (92.2) Poor15/93 (16.1)142/1831 (7.8)Median no. of lymph nodes harvested (i.q.r.) (*N* = 2961)16.0 (12.0--21.0)15.0 (11.0--21.0)0.311 Median no. of positive lymph nodes (i.q.r.) (*N* = 2958)4.0 (1.0--9.0)1.0 (0.0--3.0)\< 0.001pT stage (*N* = 2960)\< 0.001 pT11/146 (0.7)7/2814 (0.2)0.333 pT24/146 (2.7)104/2814 (3.7)0.548 pT349/146 (33.6)1918/2814 (68.2)\< 0.001 pT492/146 (63.0)785/2814 (27.9)\< 0.001pN stage (*N* = 2950)\< 0.001 pN022/144 (15.3)1229/2806 (43.8)\< 0.001 pN144/144 (30.6)970/2806 (34.6)0.323 pN278/144 (54.2)607/2806 (21.6)\< 0001Synchronous distant metastases outside the peritoneal cavity (*N* = 2969)80/147 (54.4)516/2822 (18.3)\< 0.001 Liver70/147 (47.6)460/2775 (16.6)\< 0.001 Lung24/144 (16.7)102/2763 (3.7)\< 0.001 Other17/142 (12.0)37/2751 (1.3)\< 0.001Initial intervention for acute colonic obstruction (*N* = 2976)0.422 Emergency resection121/148 (81.8)2231/2828 (78.9)0.404 Decompressing stoma20/148 (13.5)359/2828 (12.7)0.771 SEMS without SEMS-related perforation6/148 (4.1)214/2828 (7.6)0.111 SEMS with SEMS-related perforation1/148 (0.7)24/2828 (0.8)1.000Initial treatment intent\< 0.001 Curative64/148 (43.2)2461/2828 (87.0) Palliative84/148 (56.8)367/2828 (13.0)Laparoscopic approach for tumour resection (*N* = 2960)19/147 (12.9)454/2813 (16.1)0.300 Conversion (*N* = 426)5/17 (29.4)104/409 (25.4)0.777Type of resection (*N* = 2975)0.878 Sigmoid resection98/148 (66.2)1808/2827 (64.0)0.576 Left hemicolectomy38/148 (25.7)756/2827 (26.7)0.775 Subtotal colectomy11/148 (7.4)200/2827 (7.1)0.869 Extended left hemicolectomy0/148 (0.0)22/2827 (0.8)0.624 Combined sigmoid resection and right hemicolectomy0/148 (0.0)25/2827 (0.9)0.633 Transverse colectomy1/148 (0.7)16/2827 (0.6)0.581Primary anastomosis (*N* = 2515)58/148 (39.2)1324/2817 (47.0)0.063Stoma in situ directly after resection (*N* = 2929)103/144 (71.5)1759/2785 (63.2)0.042Completeness of resection (*N* = 2873) R0110/127 (86.6)2628/2746 (95.7) R1--217/127 (13.4)118/2746 (4.3)\< 0.001Median follow-up in months (i.q.r.) (*N* = 2909)16.0 (7.0--27.0)27.0 (12.0--48.0)\< 0.001*SEMS* self-expandable metal stent, *SD* standard deviation, *i.q.r.* interquartile range, *BMI* body mass index, *ASA* American Society of Anaesthesiologists

### Treatment and Survival of Synchronous PM {#Sec11}

Median follow-up of the entire cohort was 26 months (IQR 12--47). Median overall survival was 20 months (95% CI 17--23) in patients with synchronous PM and 63 months (95% CI 58--68) for patients without synchronous PM (*p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}). Three-year overall survival rates were 18.8% and 64.0%, respectively. After diagnosis of synchronous PM, 25 patients (17.0%) were treated with CRS/HIPEC.Fig. 2Overall survival in patients with versus without synchronous peritoneal metastases

Metachronous Peritoneal Metastases {#Sec12}
----------------------------------

### Baseline and Procedural Characteristics {#Sec13}

Data on peritoneal recurrence were missing in 115 of 2407 patients (4.8%). Metachronous PM developed in 210 of the 2292 evaluable patients after a median interval from primary tumor resection of 14 months (IQR 9.0--22.0). The cumulative metachronous PM rate at 1, 2 and 3 years was 3.8%, 8.0%, and 9.9%, respectively. Baseline characteristics stratified for metachronous PM are displayed in Table [2](#Tab2){ref-type="table"}. Patients with metachronous PM were significantly younger (69 vs. 71 years, *p *\< 0.001), were less often ASA III-IV (22.6% vs. 30.5%, *p* = 0.017), and fewer patients had comorbidities (62.4% vs. 70.8%, *p* = 0.012). Metachronous PM patients were more often diagnosed with pT4 stage (39.7% vs. 24.7%, *p* \< 0.001) and pN2 stage (29.2% vs. 17.1%, *p* \< 0.001), and had a higher proportion of incomplete resection (6.0% vs. 3.3%, *p* = 0.067). More patients in the metachronous PM group were treated with adjuvant systemic chemotherapy (52.9% vs. 39.7%, *p* \< 0.001).Table 2Baseline and surgical characteristics of patients who underwent curative intent resection of left-sided obstructive colon cancer, and who developed metachronous peritoneal metastases beyond 30 days postoperatively versus those who did notMetachronous peritoneal metastases\
*N* = 210 (%)No metachronous peritoneal metastases\
*N* = 2082 (%)*P*Sex (*N* = 2292)0.207 Male104/210 (49.5)1126/2082 (54.1) Female106/210 (50.5)956/2082 (45.9)Median age in years (i.q.r) (*N* = 2292)69.0 (61.0--76.0)71.0 (62.0--78.0)\< 0.001Mean BMI in kg/m^2^ (SD) (*N* = 2008)25.4 (23.2--28.4)24.9 (22.7--27.6)0.081ASA score (*N* = 2269)0.017 ASA I-II161/208 (77.4)1432/2061 (69.5) ASA III-IV47/208 (22.6)629/2061 (30.5)Comorbidity (*N* = 2283)131/210 (62.4)1467/2073 (70.8)0.012Previous abdominal surgery (*N* = 2272)52/207 (25.1)635/2065 (30.8)0.093Tumour localization (*N* = 2292)0.609 Sigmoid140/210 (66.7)1421/2082 (68.3)0.639 Descending colon38/210 (18.1)394/2082 (18.9)0.770 Splenic flexure32/210 (15.2)267/2082 (12.8)0.322Tumour histology (*N* = 2253)0.003 Adenocarcinoma188/208 (90.4)1962/2045 (95.9)\< 0.001 Mucinous tumour16/208 (7.7)72/2045 (3.5)0.003 Signet-ring cell tumour2/208 (1.0)7/2045 (0.3)0.199 Other2/208 (1.0)4/2045 (0.2)0.099Tumour differentiation (*N* = 1487)0.758 Well/moderate122/132 (92.4)1262/1355 (93.1) Poor10/132 (7.6)93/1355 (6.9)Median no. of lymph nodes examined (i.q.r.) (*N* = 2286)14.0 (11.0--20.0)15.0 (12.0--21.0)0.064Median no. of positive lymph nodes (i.q.r.) (*N* = 2281)2.0 (0.0--4.0)1.0 (0.0--2.0)\< 0.001pT stage (*N* = 2282)\< 0.001 pT11/209 (0.5)5/2073 (0.2)0.438 pT25/209 (2.4)86/2073 (4.1)0.216 pT3120/209 (57.4)1471/2073 (71.0)\< 0.001 pT483/209 (39.7)511/2073 (24.7)\< 0.001pN stage (*N* = 2277)\< 0.001 pN072/209 (34.4)1015/2068 (49.1)\< 0.001 pN176/209 (36.4)700/2068 (33.8)0.465 pN261/209 (29.2)353/2068 (17.1)\< 0.001Synchronous distant metastases outside the peritoneal cavity (*N* = 2241)23/208 (11.1)161/2033 (7.9)0.116 Liver22/208 (10.6)138/2030 (6.8)0.044 Lung1/208 (0.5)19/2030 (0.9)1.000 Other0/208 (0.0)15/2028 (0.7)0.387Initial intervention for acute colonic obstruction (*N* = 2292)0.802 Emergency resection169/210 (80.5)1602/2082 (76.9)0.245 Decompressing stoma25/210 (11.9)291/2082 (14.0)0.406 SEMS without SEMS-related perforation15/210 (7.1)174/2082 (8.4)0.542 SEMS with SEMS-related perforation1/210 (0.5)15/2082 (0.7)1.000Laparoscopic approach for tumour resection (*N* = 2280)33/209 (15.8)347/2071 (16.8)0.721 Conversion (%) (*N* = 339)6/32 (18.8)80/307 (26.1)0.366Type of resection (*N* = 2291)0.238 Sigmoid resection121/210 (57.6)1324/2081 (63.6)0.087 Left hemicolectomy65/210 (31.0)582/2081 (28.1)0.376 Subtotal colectomy19/210 (9.0)131/2081 (6.3)0.124 Extended left hemicolectomy1/210 (0.5)18/2081 (0.9)1.000 Combined sigmoid resection and right hemicolectomy2/210 (1.0)16/2081 (0.8)0.678 Transverse colectomy2/210 (1.0)8/2081 (0.4)0.232Primary anastomosis (*N* = 2283)94/209 (45.0)1014/2074 (48.9)0.280Stoma in situ directly after resection (*N* = 2255)135/207 (65.2)1263/2048 (61.7)0.316Completeness of resection (%) (*N* = 2237)0.067 R0189/201 (94.0)1969/2036 (96.7) R1--212/201 (6.0)67/2036 (3.3)Adjuvant chemotherapy (*N* = 2286)110/208 (52.9)826/2078 (39.7)\< 0.001Median time in weeks from resection until start adjuvant chemotherapy (i.q.r.) (*N* = 838)6.0 (4.0--11.0)6.0 (4.0--8.0)0.435Median follow-up in months (i.q.r.) (*N* = 2245)26.0 (16.5--39.0)32.0 (16.0--54.0)0.006*SEMS* self-expandable metal stent, *SD* standard deviation, *i.q.r.* interquartile range, *BMI* body mass index, *ASA* American Society of Anaesthesiologists

### Risk Factors for the Development of Metachronous PM in LSOCC {#Sec14}

Univariable analysis revealed the following potential predictors of metachronous PM: subtotal colectomy, pT4 stage, pN1 stage, pN2 stage, incomplete (R1--2) resection, having received adjuvant chemotherapy, and time from resection until adjuvant chemotherapy of ≥ 8 weeks (Table [3](#Tab3){ref-type="table"}). Subsequent multivariable analysis identified only pT4 stage (HR 1.78, 95% CI 1.19--2.67, *p *= 0.005) and pN2 stage (HR 2.10, 95% CI 1.21--3.65, *p* = 0.009) as independent risk factors.Table 3Cox proportional hazards regression analysis of risk factors for developing metachronous peritoneal metastases after resection of left-sided obstructive colon cancerVariableUnivariable analysisMultivariable analysisHR (95% CI)*P*HR (95% CI)*P*Age \< 60 yearsReference ≥ 60 years0.905 (0.651--1.259)0.554----ASA score ASA 1--2Reference ASA 3--40.828 (0.598--1.147)0.257----Treatment Emergency resectionReference Elective resection after DS or SEMS without perforation0.809 (0.571--1.146)0.232---- SEMS with perforation0.651 (0.091--4.653)0.669Surgical approach OpenReference Laparoscopic0.932 (0.639--1.358)0.713----Type of resection Segmental resectionReference Subtotal colectomy1.597 (0.996--2.560)0.052NSNSMajor post-resection complications NoReference Yes0.933 (0.627--1.390)0.735----Tumour histology Non-mucinousReference Mucinous2.383 (1.430--3.973)0.001NSNSpT stage pT1--3ReferenceReference pT42.176 (1.646--2.876)\< 0.0011.782 (1.191--2.668)0.005pN stage pN0ReferenceReference pN11.557 (1.127--2.152)0.0071.207 (0.696--2.094)0.503 pN22.599 (1.844--3.662)\< 0.0012.101 (1.208--3.653)0.009Location of tumour Splenic flexureReference---- Descending colon0.848 (0.528--1.361)0.495 Sigmoid0.842 (0.573--1.236)0.379Radicality R0Reference R1--22.141 (1.194--3.840)0.011NSNSAdjuvant chemotherapy NoReference Yes1.389 (1.056--1.825)0.019NSNSTime from resection until adjuvant chemotherapy \< 8 weeksReference ≥ 8 weeks1.314 (0.874--1.975)0.189NSNS*ASA* American Society of Anaesthesiologists, *DS* decompressing stoma, *SEMS* self-expandable metal stent, *NS* not significant

### Treatment and Survival of Metachronous PM {#Sec15}

Treatment of metachronous PM was judged by the local investigators as intentionally curative in 59 patients (28.6%) (Supplementary Table [1](#Tab1){ref-type="table"}), and this consisted of CRS/HIPEC in 41 patients (19.9%). A total of 147 patients (71.4%) were treated with palliative intent, mostly comprising palliative systemic therapy. Median follow-up was 31 months (IQR 15--52). Three-year overall survival was 48.1% and 77.0% for patients developing metachronous PM and patients who did not, respectively (*p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Overall survival in patients who did or did not develop metachronous peritoneal metastases as measured from time of primary tumour resection

Discussion {#Sec16}
==========

The present population based analysis of patients who underwent resection of LSOCC revealed an incidence of synchronous PM of 5%. The cumulative 3-year metachronous PM rate of the remaining patients who were treated with curative intent and were still alive at 30 days postoperatively was 9.9%. Within this clearly defined cohort of colon cancer patients who present with an emergency obstruction, pT4 and pN2 stage appeared to be independent risk factors for developing metachronous PM. A substantial prognostic impact of both synchronous and metachronous PM could be demonstrated. In both the synchronous and metachronous PM groups, less than 20% were eligible for surgical treatment of PM.

There are a few other population based studies on incidence of synchronous PM of colorectal origin. Another Dutch study from the Eindhoven Cancer registry found an incidence of 4.8% among 18,738 patients diagnosed with primary colorectal cancer between 1995 and 2008, of whom 44% had metastatic disease limited to the peritoneal cavity.[@CR13] The definition of synchronous PM was not provided and no data were given on emergency presentation. This incidence was confirmed at a national level by Van der Geest et al., reporting a 4.7% synchronous PM rate between 2008 and 2011.[@CR14] Synchronous PM were found in 477 of 11,124 colorectal cancer patients (4.3%) in the Stockholm region (1995--2007) within 1 month from diagnosis.[@CR6] This study did not provide separate data on emergency surgery or obstruction. A recent study based on the entire country of Sweden, including 35,120 colorectal and appendiceal cancers surgically treated between 2007 and 2015, reported a 2.5% incidence of synchronous PM within 6 months from diagnosis.[@CR7] Perforation close to a colon cancer was only statistically significant in univariable analysis, but emergency surgery for colon cancer remained independently associated with synchronous PM in multivariable analysis. An overall incidence of synchronous PM of 6.8% was reported in a French study including 9148 colorectal cancer patients (1976--2011) from the administrative area of Côte-d'Or in Burgundy, also using a 6-month period from diagnosis of the primary cancer. Among 737 patients with obstructing colorectal cancer, the incidence of synchronous PM was 16.2%, with a corresponding odds ratio for obstruction of 2.8 when compared with non-emergency surgery in univariable analysis.[@CR15]

The present cohort represents a certain subpopulation with only left-sided obstructing tumors. Left-sided location has been associated with lower risk of PM, whereas emergency setting and the more advanced T as well as N stage would imply a higher risk of PM if compared to an unselected colon cancer population. The 5.0% observed incidence of synchronous PM in the current study is difficult to compare with the available literature, given the varying definitions (PM diagnosed within 1--6 months), populations and time periods that were included. Using the same definition regarding diagnosis within 1 month from primary resection, the incidence of the current population with obstruction is probably only slightly higher if compared with the unselected population of Segelman et al.[@CR6]

Reported survival of synchronous PM based on registry data is generally poor, ranging from a median survival of 5 months in older studies and in combination with other metastatic sites, up to a 3-year overall survival rate of 21% with surgical treatment in more recent years.[@CR13]^,^[@CR15] Besides surgical treatment, mostly consisting of CRS/HIPEC, the use of systemic therapy has also substantially increased over the years, which translated into better survival at a population level.[@CR15]^,^[@CR16]

The 3-year metachronous PM rate of 9.9% as found in our selected population constituting left-sided obstructing colon cancer, seems substantially higher compared to unselected colon cancer populations described in the literature. A recent pooled analysis of three large randomized trials on adjuvant treatment after curative resection of stage II-III colon cancer revealed an overall crude incidence of only 2.3% (86/3714).[@CR17] Younger age (\< 60 years), pT4, pN1--2 and D2 (instead of D3) lymphadenectomy were found to be independent predictors for metachronous PM, while adjuvant chemotherapy, mucinous histology and differentiation were not associated. The authors explain the relatively low rate of metachronous PM by the fact that no perforated tumors were included in these trials, with very low rates of obstruction, emergency surgery and incomplete resection.

A previous Dutch population based study reported a crude incidence of metachronous PM of 3.4% (197/5671).[@CR18] No data on emergency setting was available. One of the reasons for the higher percentage of PM in the present study might be the fact that this is a more recent cohort of patients. Over the years, the use of CT imaging during follow-up has intensified and the quality of CT imaging has improved. A similar 4.2% metachronous PM rate was found in the previously mentioned study from Stockholm County.[@CR6] Emergency surgery was associated with higher risk of metachronous PM. Although reasons for emergency surgery were not reported, bowel perforation was separately included in the multivariable model, and did not show a significant association. The more recent data from Sweden confirmed that perforation was not associated with metachronous PM, while emergency surgery for colon cancer was independently associated with metachronous PM (HR 1.92).[@CR7] The French study by Quere et al. reported an overall cumulative incidence of metachronous PM of 5.5% at 5 years.[@CR15] Obstruction or perforation were both associated with a 10% and 12% cumulative risk of metachronous PM at 3 and 5 years, respectively, with a corresponding combined HR of 1.82 in multivariable analysis. Our study confirms these observations and supports the hypothesis that obstruction is an independent risk factor for metachronous PM.

Remarkably, observed HR for T4 of 1.8 and for N2 of 2.1 in the present study are much lower than in the published multivariable models. Segelman et al. developed a prediction model for colon and rectal cancer separately, which was subsequently validated.[@CR19]^,^[@CR20] Right-sided tumor location (HR 1.23), number of harvested lymph nodes \< 12 (HR 1.64), R1 resection (HR 1.49), R2 resection (HR 2.31) and emergency surgery (HR 2.09) were of minor influence, whereas the highest risk was observed for T4 (HR 19.44) and N2 stage (HR 4.51). External validation resulted in modification of the model with incorporation of mucinous histology, but still showing the two dominant predictors of T4 and N2 stage. The relatively low HRs as found in the present analysis are likely explained by a higher a priori risk, mainly caused by more advanced T and N stage at baseline. This might also support the finding of the French study that obstruction itself increases the risk of metachronous PM, after which the impact of TN stage is reduced.

The literature suggests that more intensified surgical and systemic treatment in selected patients with metachronous PM results in favourable survival.[@CR15]^,^[@CR16] However, the proportion of patients that are eligible for multimodality treatment including surgery is still restricted based on the present study, emphasizing the need for studies that aim for optimized detection and management of metachronous PM.[@CR21]

Limitations of the present study are related to the retrospective data collection and some degree of missing data. For example, treatment of synchronous PM was registered inconsistently with consequent limited information. Furthermore, the relative contribution of obstruction to the risk of synchronous or metachronous PM could not be determined because of the lack of a control group. Another important limitation is the difficulty of diagnosing PM with standard imaging techniques. For example, the incidence of PM in CRC patients undergoing post-mortem autopsy is even up to 40%, depending on tumour type (mucinous and signet ring cell vs. adenocarcinoma) and location.[@CR22] Nevertheless, this study adds to the currently available literature by providing up to date epidemiological data on peritoneal dissemination in patients with LSOCC.

In conclusion, this population based study revealed a 5.0% incidence of synchronous peritoneal metastases in patients who underwent resection of left-sided obstructive colon cancer. The subsequent 3-year cumulative metachronous PM rate was 9.9%, with advanced tumour and nodal stage as independent risk factors for the development of PM. This relatively high rate supports the literature suggesting that obstruction is independently associated with an increased risk of metachronous PM.
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